U.S. Hospitality Stock News

Abbott Laboratories is integrating its Precision Oncology portfolio into Flatiron Health's OncoEMR platform used by a wide U.S. oncology network. The move brings Abbott's advanced cancer diagnostics directly into clinicians' electronic workflows, aiming to simplify ordering and results review. This development follows Abbott's expansion into cancer diagnostics through its deal with Exact Sciences. For investors tracking NYSE:ABT, this news sits against a mixed share price picture. The stock...

Wondering if DRDGOLD at around US$27.65 still offers value, or if most of the easy gains are already behind it? This article walks through what the current price might imply. The stock has returned 1.7% over the last 7 days, while the 30 day return sits at a 28.9% decline, against an 8.8% decline year to date and an 81.5% return over the past year, with a very large 3 year and 226.1% 5 year return. Recent coverage has focused on DRDGOLD as part of broader gold and precious metals...

Recent performance snapshot for D.R. Horton D.R. Horton (DHI) has seen its share price move lower recently, with a 1 day return of a 1.2% decline, a 7 day return of a 4.5% decline, and a 1 month return of a 17.4% decline. Over longer periods, the stock shows a past 3 month return of an 8.9% decline, a year-to-date return of a 9.1% decline, and a 1 year total return of 5.5%, alongside a 3 year total return of 39.1% and a 5 year total return of 50.4%. See our latest analysis for D.R...

If you are wondering whether Elevance Health's current share price reflects its true worth, this article will walk you through what the numbers actually say. Recently, the stock has retreated, with returns of a 1.5% decline over 7 days, an 11.0% decline over 30 days, a 19.6% decline year to date, and a 33.1% decline over the past year from a last close of US$284.79. These moves have arrived alongside ongoing sector attention on large managed care names and investor focus on how insurers are...

In March 2026, Academy Sports and Outdoors, Inc. reported fourth-quarter sales of US$1,718.47 million and net income of US$133.69 million, issued full-year 2027 guidance, and confirmed completion of a share repurchase program totaling 5,089,876 shares for US$263.51 million. While full-year sales edged up to US$6,053.41 million but net income softened to US$376.77 million, the combination of higher fourth-quarter earnings per share and ongoing buybacks highlights how capital allocation and...

Visa (V) continues to attract attention from investors after recent share price weakness, with the stock down about 6% over the past month and 15% over the past 3 months, which has sharpened the focus on its fundamentals. See our latest analysis for Visa. Visa's recent share price weakness, including a 6.4% 30 day share price return decline and a 15.3% 90 day share price return decline, contrasts with its 3 year total shareholder return of 33.8% and 5 year total shareholder return of 41.9%...

If you are wondering whether Globus Medical's current share price offers fair value or not, the recent trading pattern gives you plenty to think about. The stock closed at US$83.51, with returns of a 4.2% decline over the last 7 days and a 12.5% decline over 30 days, while still sitting on a 14.1% gain over 1 year, 46.7% over 3 years and 33.0% over 5 years. Recent news coverage has focused on Globus Medical's position in the medical devices space and how its product portfolio fits into long...

In March 2026, Century Aluminum announced that Levi Chaffin has been promoted to Senior Vice President of Operations, Americas, overseeing its U.S. and Jamaican operations after previously managing the Sebree smelter and its roughly 650-person workforce. This internal promotion places an operations-focused leader with deep engineering, reliability, and process-improvement credentials at the center of Century’s Americas footprint, potentially sharpening execution across its key assets. Next,...

Nu Holdings (NYSE:NU) has drawn investor attention after recent share price pressure, with the stock down about 10% over the past month and nearly 20% in the past 3 months. See our latest analysis for Nu Holdings. While the recent 30-day share price return of about a 10% decline and year-to-date share price return of about a 21% decline suggest fading short-term momentum, the 1-year and 3-year total shareholder returns of about 32% and about 3x show that longer-term holders have still seen...

Astrana Health, Inc. recently filed two shelf registrations, including a US$120.95 million ESOP-related offering for 5,000,000 common shares and a broad omnibus shelf covering common and preferred stock, debt, warrants, and other securities. This expanded financing toolkit gives Astrana Health more flexibility to issue different types of securities, potentially reshaping its capital structure and funding options for future growth initiatives. Next, we'll examine how this expanded shelf...

Exelon (EXC) is back on some investors’ radar after recent trading, with the stock last closing at $49.11. That price sits against a mixed pattern of short and longer term total returns. See our latest analysis for Exelon. Recent trading has added to Exelon’s 11.82% year to date share price return and 12.66% 90 day share price return. Longer term total shareholder returns of 10.75% over 1 year and 84.27% over 5 years indicate steady compounding. If you are comparing Exelon with other...

If you are looking at Halozyme Therapeutics and wondering whether the current share price reflects its true worth, this breakdown will help you make sense of what you are paying for. The stock recently closed at US$62.13, with returns of 1.2% decline over 7 days, 10.6% decline over 30 days, 11.6% decline year to date and 2.6% decline over 1 year, set against gains of 60.4% over 3 years and 44.7% over 5 years. Recent coverage has focused on how the share price has moved over different time...

If you are wondering whether Kinsale Capital Group's current share price still reflects good value, the recent moves in the stock give you plenty to think about. The shares last closed at US$336.69, with a 2.6% gain over the past week, set against declines of 13.6% over 30 days, 14.2% year to date and 30.7% over the past year. These price moves have kept Kinsale on the radar for investors who track longer term return profiles, with the stock showing 12.2% over 3 years and 99.1% over 5 years...

Recently, BioMarin Pharmaceutical discontinued three Phase 2 Voxzogo studies following safety concerns, while simultaneously reporting encouraging clinical and real-world outcomes for the drug in other settings. The company and analysts now suggest that Voxzogo’s safety issues may be limited to specific uses, with BioMarin’s broader outlook increasingly supported by its wider rare-disease portfolio. Now we’ll explore how the Voxzogo safety-driven trial discontinuations, alongside positive...

Wondering if Netflix at around US$92.97 is a bargain or a trap? This article breaks down what that price really implies about the business. The stock has been relatively flat over the last year with a return of around a 0.3% decline, while the 3 year return of 166.9% and 5 year return of 72.0% show how different the picture can look over longer periods. Recent coverage around Netflix has focused on its position as a major streaming platform and how shifts in subscriber expectations,...

Gibraltar Industries (ROCK) has been drawing attention after a period of weaker share performance, with the stock showing declines over the past month, past 3 months, year to date and over the past year. See our latest analysis for Gibraltar Industries. At a share price of $39.50, Gibraltar Industries has seen momentum fade, with a 30 day share price return of 13.15% and a 1 year total shareholder return of 32.66% in decline. If weak recent share price returns have you reassessing your...

Kroger (KR) has recently introduced in-store price cuts and expanded fuel savings events as gas prices climb, putting its approach to customer value and traffic front and center for investors watching the stock. See our latest analysis for Kroger. The recent price cuts and fuel savings push come at a time when the share price has shown firm momentum, with a 30 day share price return of 8.03% and a 90 day share price return of 17.61%. The 5 year total shareholder return of 123.20% reflects a...

CIM Real Estate Finance Trust (OTCPK:CMRF) has wrapped up FY 2025 with fourth quarter revenue of US$97.9 million and basic EPS of US$0.07, giving investors a clean snapshot of how the year finished. Over recent periods, revenue has shifted from US$121.4 million in Q3 2024 to US$106.2 million in Q4 2024, then to US$106.4 million in Q1 2025, US$107.2 million in Q2 2025, US$104.5 million in Q3 2025 and US$97.9 million in Q4 2025, while quarterly EPS moved from US$0.02 to an interim loss before...

If you are wondering whether Altria Group's current share price still reflects good value or if most of the upside has already been priced in, this breakdown is designed to give you a clear, structured view of what you are really paying for. With the stock at US$67.02 and returns of 4.1% over 7 days, a 2.9% decline over 30 days, 16.9% year to date and 19.5% over 1 year, recent moves suggest shifting views on both opportunity and risk. Recent coverage has continued to focus on Altria's...

On March 25, 2026, Raymond James analyst Justin Jenkins upgraded CVR Energy (NYSE: CVI) to Market Perform, highlighting the company’s refining portfolio as well positioned for a strong margin backdrop and acknowledging management’s optimism on refining demand and supply trends. This upgrade underscores how investor sentiment around refining exposure and perceived portfolio quality can play a meaningful role in how CVR Energy is viewed relative to its peers. Next, we’ll examine how this...

Ulta Beauty (NasdaqGS:ULTA) is expanding its K-Beauty World platform, giving viral Korean beauty brands faster access to the U.S. market. The company is doubling the number of e-commerce fulfillment stores and using AI tools to manage online orders and inventory. Brands that gain traction online, such as Dr. Melaxin, are moving quickly into nationwide in-store distribution across Ulta's network. Ulta Beauty operates as a multi brand beauty retailer, combining cosmetics, skincare, haircare,...

This article examines whether Compass at US$6.84 may represent attractive value or a potential value trap by exploring what the current price could be implying about the business. The stock has come under pressure recently, with a 19.2% decline over the last 7 days, 29.8% over 30 days, 34.9% year to date, and 21.6% over the past year, following a very large 3-year gain of 110.5% and a 5-year decline of 63.2%. Recent coverage has highlighted Compass as a real estate platform operating in a...

Wondering whether Viasat at around US$43.72 is still offering value or if most of the opportunity is already priced in? This article breaks down what the current share price might be implying. The stock has returned 16.2% year to date and 319.6% over the past year, even though the last 7 days and 30 days show declines of 11.1% and 4.5% respectively. Recent headlines have focused on Viasat's position in satellite communications and its role in providing connectivity services, which has kept...

If you are wondering whether Vistra's share price still reflects good value after its long run, or if the best days are already priced in, this article walks you through what the numbers say. The stock last closed at US$147.54, with returns showing a 2.5% decline over 7 days, a 15.2% decline over 30 days, a 10.7% decline year to date, and a 26.3% gain over the past year. The 3-year return is very large and the 5-year return is also very large. Recent moves in the share price have put more...